Advertisement
Journal Home
Search for

Volume 37, Issue 12, Pages 1393-1399 (December 2009)


View previous. 4 of 11 View next.

Downregulation of GATA-2 and overexpression of adipogenic gene-PPARγ in mesenchymal stem cells from patients with aplastic anemia

Yinyan Xua, Yoshiyuki Takahashia, Yue Wangab, Asahito Hamaa, Nobuhiro Nishioa, Hideki Muramatsua, Makito Tanakaa, Nao Yoshidaa, Itzel Bustos Villalobosa, Hiroshi Yagasakia, Seiji KojimaaCorresponding Author Informationemail address

Received 25 March 2009; received in revised form 12 September 2009; accepted 17 September 2009. published online 23 September 2009.

Aplastic anemia (AA) is characterized by a reduced number of hematopoietic stem cells and fatty replacement in the bone marrow. Transcriptional factor GATA-2 plays several important roles in both hematopoiesis and adipogenesis. Decreased levels of GATA-2 compromise the proliferation and survival of hematopoietic stem cells. GATA-2 suppresses adipocyte differentiation through direct inhibition of adipogenic factors, including peroxisome proliferator-activated receptor−γ (PPARγ). Previous studies have shown that expression of GATA-2 is decreased in marrow CD34-positive cells in AA. To elucidate the mechanisms of fatty marrow replacement, we evaluated the mRNA expression for GATA-2 and PPARγ in mesenchymal stem cells (MSCs) from patients with AA by quantitative real-time polymerase chain reaction. GATA-2 expression by MSCs from AA patients was significantly lower than in normal subjects. Conversely, expression of PPARγ was significantly higher in AA patients. Western blot analysis demonstrated that protein levels of GATA-2 were lower in AA patients than those in normal subjects. Moreover, incubation with interferon-γ induced downregulation of GATA-2 levels in MSCs from normal subjects. These findings indicate that fatty marrow replacement in AA patients can be explained by downregulation of GATA-2 and overexpression of PPARγ in MSCs. Decreased expression of GATA-2 might be responsible for the pathogenesis and development of the clinical features of the disease.

a Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

b Department of Pediatrics, the First Hospital of Jilin University, Changchun, Jilin, China

Corresponding Author InformationOffprint requests to: Seiji Kojima, M.D., Ph.D., Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

PII: S0301-472X(09)00366-X

doi:10.1016/j.exphem.2009.09.005


View previous. 4 of 11 View next.